Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? (Q37992956)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Maria Rosaria Rizzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Matteo Monami

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Raffaele Marfella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Edoardo Mannucci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

8 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

218-233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12325-012-0008-x

25 January 2020

exact match

0 references

cites work

The growing burden of diabetes mellitus in the US elderly population.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Mortality in older people with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Cognitive dysfunction is associated with poor diabetes control in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Key priorities in managing glucose control in older people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Type 2 diabetes and risk for functional decline and disability in older persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Neurocognitive impairment and comorbid depression in patients of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Diabetes in elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Moving against frailty: does physical activity matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Older women with diabetes have a higher risk of falls: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0008-X

10.1007/S12325-012-0008-X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22411425%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference